Compare Cisco Systems Inc (CSCO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs Novavax Inc — how do they compare? Cisco Systems Inc trades at $116.3 (market cap $452.96B), while Novavax Inc trades at $11.09 (market cap $1.82B). The key difference: Cisco Systems Inc is far larger — about 248.9× Novavax Inc's market cap, and Cisco Systems Inc pays a 1.46% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Novavax Inc for 59 Days on average.
| CSCO | NVAX | |
|---|---|---|
Market Cap | $452.96B | $1.82B |
Volume | 12,951,578 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $130.00 | $12.56 |
52-Week Low | $67.46 | $6.22 |
Typical Hold Time | 86 Days | 59 Days |
Enterprise Value | $466.58B | $1.39B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $117.39, down 0.47% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.22, and revenue growth is supported by AI-driven networking demand. Valuation ratios are elevated with a P/E of 34.5, while profitability remains robust with a net income margin of 20.95%.
The outlook is positive given AI infrastructure growth and consistent earnings beats, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $129.77 price target, implying potential upside. Key risks include execution challenges in integrating AI innovations and macroeconomic sensitivity.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
